Journal
LANCET
Volume 384, Issue 9943, Pages 618-625Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(14)61217-4
Keywords
-
Categories
Funding
- AstraZeneca
- BristolMyersSquibb
- National Institutes of Health
- Netherlands Organisation for Scientific Research
Ask authors/readers for more resources
The cholesterol contained within HDL is inversely associated with risk of coronary heart disease and is a key component of predicting cardiovascular risk. However, despite its properties consistent with atheroprotection, the causal relation between HDL and atherosclerosis is uncertain. Human genetics and failed clinical trials have created scepticism about the HDL hypothesis. Nevertheless, drugs that raise HDL-C concentrations, cholesteryl ester transfer protein inhibitors, are in late-stage clinical development, and other approaches that promote HDL function, including reverse cholesterol transport, are in early-stage clinical development. The final chapters regarding the effect of HDL-targeted therapeutic interventions on coronary heart disease events remain to be written.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available